For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| Revenue | 0 | 70 | 250 | |
| General and administrative | - | - | 3,019 | |
| Research and development | 1,959 | 2,253 | 2,834 | |
| General and administrative | 2,455 | 2,685 | - | |
| Total operating expenses | 4,414 | 4,938 | 5,852 | |
| Operating loss | -4,414 | -4,868 | -5,602 | |
| Investment income, net | 183 | 216 | 471 | |
| Other expense, net | -18 | -7 | -64 | |
| Total other income | 165 | 209 | 407 | |
| Net loss before benefit from income taxes and noncontrolling interests | -4,249 | -4,659 | -5,196 | |
| Benefit from income taxes | 0 | 0 | -199 | |
| Net loss | -4,249 | -4,659 | -4,996 | |
| Less - net income (loss) attributable to noncontrolling interests | 0 | 0 | - | |
| Net loss attributable to lisata therapeutics, inc. common stockholders | -4,249 | -4,659 | -4,996 | |
| Basic shares (in shares) | 8,738,000 | 8,605,000 | 2,082,250 | |
| Diluted shares (in shares) | 8,738,000 | 8,605,000 | 2,082,250 | |
| Lisata therapeutics, inc. common stockholders - diluted (in usd per share) | -0.49 | -0.54 | -0.6 | |
| Lisata therapeutics, inc. common stockholders- basic (in usd per share) | -0.49 | -0.54 | -0.6 | |
LISATA THERAPEUTICS, INC. (LSTA)
LISATA THERAPEUTICS, INC. (LSTA)